RANK ligand: Effects of inhibition

Current Oncology Reports

Volumn 12, Issue 2, 2010, Pages 80-86

  George, Saby ^a   Brenner, Andrew ^a   Sarantopoulos, John ^a   Bukowski, Ronald M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bone metastasis; Inhibition; Monoclonal antibody; Osteoporosis; RANK ligand

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; ARTHRALGIA; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CALCIUM INTAKE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MATURATION; CELLULITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; FATIGUE; HIP FRACTURE; HUMAN; IMMUNOMODULATION; INFECTION; JAW OSTEONECROSIS; LIMB PAIN; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DISEASES; CELL DIFFERENTIATION; HUMANS; MICE; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 77952243625     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0088-1     Document Type: Review

References (34)

1. RE Coleman 2001 Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165 176 10.1053/ctrv.2000.0210 1:CAS:528:DC%2BD3MXktlCktb4%3D 11417967 (Pubitemid 32452017)
2. BI Carlin GL Andriole 2000 The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma Cancer 88 2989 2994 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q 1:STN:280:DC%2BD3czlsVOjtQ%3D%3D 10898342
3. N Nakagawa M Kinosaki K Yamaguchi, et al. 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis Biochem Biophys Res Commun 253 395 400 10.1006/bbrc.1998.9788 1:CAS:528:DyaK1MXhs12ntw%3D%3D 9878548 (Pubitemid 29026714)
4. H Kim HK Choi JH Shin, et al. 2009 Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice J Clin Invest 119 813 815 10.1172/JCI36809 1:CAS:528:DC%2BD1MXktlSntrg%3D 19258703
5. M Asagiri H Takayanagi 2007 The molecular understanding of osteoclast differentiation Bone 40 251 264 10.1016/j.bone.2006.09.023 1:CAS:528: DC%2BD2sXmtVCrtA%3D%3D 17098490 (Pubitemid 46054562)
6. BR Wong R Josien SY Lee, et al. 1998 The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor J Biol Chem 273 28355 28359 10.1074/jbc.273.43.28355 1:CAS:528:DyaK1cXntVClsL4%3D 9774460 (Pubitemid 28496137)
7. S Ghosh MJ May EB Kopp 1998 NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses Annu Rev Immunol 16 225 260 10.1146/annurev.immunol.16.1.225 1:CAS:528:DyaK1cXislygtL0%3D 9597130 (Pubitemid 28183365)
8. G Bonizzi M Karin 2004 The two NF-kappaB activation pathways and their role in innate and adaptive immunity Trends Immunol 25 280 288 10.1016/j.it.2004.03.008 1:CAS:528:DC%2BD2cXktVKqs7s%3D 15145317 (Pubitemid 38610351)
9. S Memet 2006 NF-kappaB functions in the nervous system: from development to disease Biochem Pharmacol 72 1180 1195 10.1016/j.bcp.2006.09.003 1:CAS:528:DC%2BD28XhtVagtrzO 16997282 (Pubitemid 44465848)
10. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 10.1016/S0092-8674(00)81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D 9568710 (Pubitemid 28180851)
11. DM Anderson E Maraskovsky WL Billingsley, et al. 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 175 179 10.1038/36593 1:CAS:528:DyaK2sXnsVOgurY%3D 9367155 (Pubitemid 27507987)
12. A Fouque-Aubert R Chapurlat 2008 Influence of RANKL inhibition on immune system in the treatment of bone diseases Joint Bone Spine 75 5 10 10.1016/j.jbspin.2007.05.004 1:CAS:528:DC%2BD1cXjtVKns7w%3D 17920324 This article provides a very good review of the influence of RANKL inhibition on immune system
13. P Li EM Schwarz RJ O'Keefe, et al. 2004 RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis J Bone Miner Res 19 207 213 10.1359/JBMR.0301233 1:CAS:528: DC%2BD2cXhs1emu7s%3D 14969390 (Pubitemid 38116734)
14. D Seshasayee H Wang WP Lee, et al. 2004 A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response J Biol Chem 279 30202 30209 10.1074/jbc.M403968200 1:CAS:528:DC%2BD2cXlsFKitLY%3D 15145935 (Pubitemid 38937945)
15. BR Wong R Josien SY Lee, et al. 1997 TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor J Exp Med 186 2075 2080 10.1084/jem.186.12.2075 1:CAS:528:DyaK2sXotVGhsb4%3D 9396779 (Pubitemid 28013694)
16. MF Bachmann BR Wong R Josien, et al. 1999 TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation J Exp Med 189 1025 1031 10.1084/jem.189.7.1025 1:CAS:528:DyaK1MXitlemsbc%3D 10190893 (Pubitemid 29169819)
17. S Kitazawa R Kitazawa 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions J Pathol 198 228 236 10.1002/path.1199 1:CAS:528:DC%2BD3sXivV2js74%3D 12237883 (Pubitemid 35243881)
18. PI Croucher CM Shipman J Lippitt, et al. 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma Blood 98 3534 3540 10.1182/blood.V98.13.3534 1:CAS:528:DC%2BD3MXptFOjsbY%3D 11739154
19. JR Canon M Roudier R Bryant, et al. 2008 Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis Clin Exp Metastasis 25 119 126 10.1007/s10585-007-9127-1 1:CAS:528:DC%2BD1cXmtFyhtbs%3D 18064531
20. J Zhang J Dai Y Qi, et al. 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 107 1235 1244 10.1172/JCI11685 1:CAS:528:DC%2BD3MXjsl2ntr0%3D 11375413 (Pubitemid 32494540)
21. R Eastell R Hannon 2005 Long-term effects of aromatase inhibitors on bone J Steroid Biochem Mol Biol 95 151 154 10.1016/j.jsbmb.2005.04.009 1:CAS:528:DC%2BD2MXntVOhtb8%3D 15970439 (Pubitemid 41137305)
22. M Baum A Buzdar J Cuzick, et al. 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802 1810 10.1002/cncr.11745 1:CAS:528:DC%2BD3sXpt1arsbc%3D 14584060 (Pubitemid 37310221)
23. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D 15014181 (Pubitemid 38298988)
24. PE Goss JN Ingle S Martino, et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D 14551341 (Pubitemid 37362955)
25. GK Ellis HG Bone R Chlebowski, et al. 2008 Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 4875 4882 10.1200/JCO.2008.16.3832 1:CAS:528: DC%2BD1cXhtlGitrzO 18725648 This article demonstrates how denosumab resulted in a statistically significant increase in BMD at 12 and 24 months in estrogen receptor-positive metastatic breast cancer patients receiving AI therapy
26. A Lipton GG Steger J Figueroa, et al. 2008 Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy Clin Cancer Res 14 6690 6696 10.1158/1078-0432.CCR-07- 5234 1:CAS:528:DC%2BD1cXht1Kgur3M 18927312
27. A Lipton GG Steger J Figueroa, et al. 2007 Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases J Clin Oncol 25 4431 4437 10.1200/JCO.2007.11. 8604 1:CAS:528:DC%2BD2sXht1ertrjP 17785705 (Pubitemid 350013849)
28. Stopeck A: A comparison of denosumab versus zoledronic acid on the incidence of skeletal-related events in breast cancer patients with bone metastases [abstract 22]. Presented at the 32nd Cancer Therapy and Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium. San Antonio, TX; December 9-13, 2009.
29. Stopeck, A, Body, JJ, Fujiwara Y, et al.: Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. In European Society for Medical Oncology, Berlin 2009. Presented at the European Society for Medical Oncology. Berlin, Germany; September 20-24, 2009.
30. MR Smith B Egerdie N Hernandez Toriz, et al. 2009 Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 745 755 10.1056/NEJMoa0809003 1:CAS:528:DC%2BD1MXhtVWls7rF 19671656 This study showed that denosumab statistically increased BMD and decreased vertebral fractures in patients with nonmetastatic prostate cancer receiving ADT
31. K Fizazi A Lipton X Mariette, et al. 2009 Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 1564 1571 10.1200/JCO.2008.19.2146 1:CAS:528:DC%2BD1MXltVOhtr0%3D 19237632
32. Fizazi K, Bosserman L, Gao G, et al.: Denosumab in patients with bone metastases from castration-resistant prostate cancer and elevated bone resorption despite intraenous bisphosphonate (IV BP) therapy: analysis of a randomized phase II trial. Presented at the European Society for Medical Oncology. Berlin, Germany; September 20-24, 2009.
33. Henry DR: A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Presented at the European Society for Medical Oncology. Berlin, Germany; September 20-24, 2009.
34. SR Cummings J San Martin MR McClung, et al. 2009 Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 756 765 10.1056/NEJMoa0809493 1:CAS:528:DC%2BD1MXhtVWls7nF 19671655 This large randomized study showed that fractures were significantly decreased (HR, 0.32) in osteoporotic postmenopausal women when treated with denosumab twice yearly for 36 months